>
Celon Pharma SA logo

CLNA - Celon Pharma SA Share Price

PLN39.5 0.8  2.1%

Last Trade - 21/09/21

Sector
Healthcare
Size
Mid Cap
Market Cap £663.4m
Enterprise Value £663.8m
Revenue £32.2m
Position in Universe 59th / 799
Bullish
Bearish
Unlock CLNA Revenue
Momentum
Relative Strength (%)
1m +0.84%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.62%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
126.7 128.8 107.1 125.2 102.2 139.3 196.6 237.5 +1.9%
-7.9 -48.9 +15.0 -61.0 +83.4 -98.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Celon PharmaSA revenues increased 36% to PLN105.1M. Net incomeapplicable to common stockholders decreased 69% to PLN302K.Revenues reflect Generic Medicines segment increase of 34%to PLN93.6M, Innovative segment increase of 55% to PLN11.5M, Foreign segment increase from PLN20.3M to PLN49.7M. Netincome was offset by Innovative segment loss increase of 5%to PLN22.1M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CLNA Revenue Unlock CLNA Revenue

Net Income

CLNA Net Income Unlock CLNA Revenue

Normalised EPS

CLNA Normalised EPS Unlock CLNA Revenue

PE Ratio Range

CLNA PE Ratio Range Unlock CLNA Revenue

Dividend Yield Range

CLNA Dividend Yield Range Unlock CLNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CLNA EPS Forecasts Unlock CLNA Revenue
Profile Summary

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated October 25, 2012
Public Since April 13, 2009
No. of Shareholders: n/a
No. of Employees: 514
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Warsaw Stock Exchange
Shares in Issue 96,000,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CLNA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CLNA
Upcoming Events for CLNA
Frequently Asked Questions for Celon Pharma SA
What is the Celon Pharma SA share price?

As of 21/09/21, shares in Celon Pharma SA are trading at PLN39.5, giving the company a market capitalisation of £663.4m. This share price information is delayed by 15 minutes.

How has the Celon Pharma SA share price performed this year?

Shares in Celon Pharma SA are currently trading at PLN39.5 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celon Pharma SA price has moved by % over the past year.

What are the analyst and broker recommendations for Celon Pharma SA?

There are no analysts currently covering Celon Pharma SA.

When will Celon Pharma SA next release its financial results?

Celon Pharma SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Celon Pharma SA dividend yield?

Celon Pharma SA does not currently pay a dividend.

Does Celon Pharma SA pay a dividend?

Celon Pharma SA does not currently pay a dividend.

When does Celon Pharma SA next pay dividends?

Celon Pharma SA does not currently pay a dividend.

How do I buy Celon Pharma SA shares?

To buy shares in Celon Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Celon Pharma SA?

Shares in Celon Pharma SA are currently trading at PLN39.5, giving the company a market capitalisation of £663.4m.

Where are Celon Pharma SA shares listed? Where are Celon Pharma SA shares listed?

Here are the trading details for Celon Pharma SA:

Country of listing: Poland
Exchange: WSE
Ticker Symbol: CLNA
What kind of share is Celon Pharma SA?

Based on an overall assessment of its quality, value and momentum, Celon Pharma SA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Celon Pharma SA share price forecast 2021?

Shares in Celon Pharma SA are currently priced at PLN39.5. At that level they are trading at 20.91% discount to the analyst consensus target price of 0.00.

Analysts covering Celon Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of 0.007 for the next financial year.

How can I tell whether the Celon Pharma SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celon Pharma SA. Over the past six months, the relative strength of its shares against the market has been %. At the current price of PLN39.5, shares in Celon Pharma SA are trading at 0.27% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Celon Pharma SA PE Ratio?

The Celon Pharma SA PE ratio based on its reported earnings over the past 12 months is 1.85k. The shares are currently trading at PLN39.5.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Celon Pharma SA?

We were unable to find the directors for Celon Pharma SA.

Who are the major shareholders of Celon Pharma SA?

Here are the top five shareholders of Celon Pharma SA based on the size of their shareholding:

Similar to CLNA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.